News
From J&J to BMS, New Jersey pharmaceutical companies continue to expand and transform through M&A, leadership shifts and ...
Verona Pharma has seen its stock price jump by 125 percent year-to-date, closing at $104.74 versus $46.44 in the last trading ...
Merck aims to boost its business by buying Verona Pharma for $10 billion. Through the deal, it will add Ohtuvayre -- a ...
23h
PHILADELPHIA.Today on MSNWSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration NearsMerck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
Private equity work is up year-over-year, but tariffs, inflation and valuations continue to be an issue for dealmakers.
Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...
Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings ...
3d
TipRanks on MSNMerck Stock (MRK) Bulls Cheer $10Bn Verona Pharma GambleMerck & Co. ($MRK) is betting on acquisitions to offset the looming revenue loss from the upcoming patent expiration of ...
Pharmaceutical titan Merck & Co. Inc. has announced a landmark $10 billion acquisition of Verona Pharma plc, underscoring its ...
US Foods Holding stock hit an all-time high Friday on a report that the firm was mulling an acquisition of Performance Food ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results